Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cv Sciences Inc (OP: CVSI )

0.0473 -0.0037 (-7.25%)
Streaming Delayed Price Updated: 3:55 PM EDT, Sep 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cv Sciences Inc

< Previous 1 2 3 Next >
Cannabis Stock Gainers And Losers From July 28, 2023
Via Benzinga
Marijuana Stock Movers For July 17, 2023
Via Benzinga
CV Sciences FY22 Revenue Declines 19% To $16.2M
CV Sciences, Inc. (OTCQB: CVSI) FY 2022 revenue was $16.2 million, a 19% decrease compared to $20.0 million for 2021. Q4 2022 Financial Highlights 
Via Benzinga
Cannabis Stock Gainers And Losers From July 26, 2023
Via Benzinga
Bullish Thursday For Marijuana Stocks - Choom Holdings, EVIO Among Top Gainers
Via Benzinga
Why Is CV Sciences Stock Up Today?
CV Sciences (OTCQB: CVSI) shares were trading 10.69% higher at $0.044 per share at the time of writing Monday morning on company's third-quarter financial results. 
Via Benzinga
CV Sciences Adds +PlusCBD Relief Softgels To Wellness Line Of CBD Products
CV Sciences, Inc. (OTCQB:CVSI) added +PlusCBD ... 
Via Benzinga
Cannabis Stock Movers For July 24, 2023
Via Benzinga
Marijuana Stock Movers For July 12, 2023
Via Benzinga
Nutrition Giant GNC To Distribute CBD Products In 770 Stores In US
Hemp cannabidiol (CBD) products maker CV Sciences, Inc. (OTCQB: 
Via Benzinga
Cannabis Stock Movers For July 19, 2023
Via Benzinga
Cannabis Stock Gainers And Losers From July 11, 2023
Via Benzinga
Cannabis Stock Movers For July 10, 2023
Via Benzinga
CV Sciences Inc Q1 Revenue Stagnates YoY, Here Is What You Need To Know
CV Sciences, Inc. (OTCQB: CVSI) released its financial results today for the first quarter ended March 31, 2023, revealing revenues of $4.1 million for the first quarter of 2023 compared to $4.4... 
Via Benzinga
Popular CBD Brand Questions Study: 'Misleading To Consumers And Damaging To The Industry'
NextEvo Naturals recently released results from a third-party study on 16 CBD products that were allegedly randomly selected for the research. The brand commissioned Coral Reef Labs to conduct this... 
Via Benzinga
CBD And Nicotine Formula To Treat Smokeless Tobacco Addiction Receives Patent From Japan, FDA Approval Next
CV Sciences, Inc. (OTCQB: CVSI) received a formal certificate of grant from the Japan Patent Office for its patent application 7216697. 
Via Benzinga
Biden's Pardon For Cannabis Offenders: 27 Reactions From Politicians, Industry Executives And Advocacy Orgs
President Joe Biden announced on Thursday that he will pardon all prior federal offenses for simple marijuana possession, sending  
Via Benzinga
The CBD Gold Rush Is Over (And That's A Great Thing For Consumers)
By Bharat Ayyar Disclaimer: I am not a financial advisor. Nothing contained in this post should be construed as investment advice. CV Sciences (OTC: CVSI), the company behind +PlusCBD, had a meteoric... 
Via Benzinga
Marijuana As An Appetite Suppressant? It's A Possibility
Using cannabis as an appetite suppressant for weight management may seem counterintuitive, but one rare cannabinoid may have just that effect. Delta-9 (d-9)-dominant tetrahydrocannabivarin (THCV) has... 
Via Benzinga
CV Sciences Q1 Revenue Down 8.33%, CEO Encouraged As PlusCBD Brand Gains Market Share
CV Sciences, Inc. (OTCQB: CVSI) released its financial results for the quarter ended March 31, 2022, revealing a revenue drop of 8.33% to $4.4 million YoY. First Quarter 2022 and Recent Financial and... 
Via Benzinga
A Preview Of CV Sciences's Earnings
CV Sciences (OTC:CVSI) is set to give its latest quarterly earnings report on Thursday, 2022-03-31. Here's what investors need to know before the announcement. Analysts estimate that CV Sciences will... 
Via Benzinga
Dry January Got You Down? Cannabis To The Rescue With Tokes, Yummy Gummies And More
After the hustle and bustle of the holidays, many people are looking to curtail their consumption of alcohol and are therefore partaking in 
Via Benzinga
CV Sciences Launches +PlusCBD Pain Relief Topicals With Products For Athletes, Arthritis Patients
CV Sciences, Inc. (OTCQB:CVSI) is launching +PlusCB... 
Via Benzinga
Is Medical Marijuana Really A Slippery Slope? CVSI Distribution Agreement with GNC
The Best Daily Overview Of The Cannabis Space CV Sciences Announces New Distribution Agreement with GNC. $CVSI ... 
Via Benzinga
Trending Up: $TLLTF $VRNOF $UNRV, GOP Cannabis Bill, Cause for Hope? — Cannabis Daily November 16, 2021
The Best Daily Overview Of The Cannabis Space Representativ... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
CV Sciences 3Q Financials Continue To Improve Cost Structure, Praises California CBD Legislation
CV Sciences, Inc. (OTCQB:CVSI), a supplier and manufacturer... 
Via Benzinga
Topics Supply Chain
Exposures Supply Chain
The Week In Cannabis: Stocks Down, Republican Legalization Bill, Germany, Uruguay, Earnings, New ETF And More
Below is a recap of the main news related to the cannabis industry and markets for the week of November 15, 2021. 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Earnings Preview For CV Sciences
CV Sciences (OTC:CVSI) is set to give its latest quarterly earnings report on Monday, 2021-11-15. Here's what investors need to know before the announcement. Analysts estimate... 
Via Benzinga
EXCLUSIVE: CV Sciences Launches New Product Line Featuring Full Range Of Phytocannabinoids
CV Sciences Inc (OTC:CVSI) is launching a ne... 
Via Benzinga
Pharmaceutical & Hemp Wellness Segments Of Cannabidiol Market Could See the Fastest Growth Rates Through 2028
Palm Beach, FL – November 15, 2021 – FinancialNewsMedia.com News Commentary – Out of all cannabinoids, cannabidiol is most widely used for therapeutic reasons due to the lack of psychoactive effects.... 
Via FinancialNewsMedia
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.